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The CHOIR trial in anemic patients with chronic kidney
disease compared epoetin-alfa treatment with low (11.3 g/l)
and high (13.5g/l) hemoglobin targets on the composite end
point of death, hospitalization for heart failure, stroke, and
myocardial infarction. However, other anemia management
trials in patients with chronic kidney disease found there
was increased risk when hemoglobin is targeted above
13g/dl. In this secondary analysis of the CHOIR trial, we
compared outcomes among the subgroups of patients with
diabetes and heart failure to describe the comparative
relationship of treatment to these two different hemo-
globin goals. By Cox regression analysis, there was no
increased risk associated with the higher hemoglobin target
among patients with heart failure. In patients without heart
failure, however, the hazard ratio (1.86) associated with
the higher target was significant. Comparing survival curves
in an unadjusted model, patients with diabetes did not
have a greater hazard associated with the higher target.
Subjects without diabetes had a significantly greater hazard
in the high as compared to the low target, but the interac-
tion between diabetes and the target was not significant.
We suggest that the increased risks associated with higher
hemoglobin targets are not clinically apparent among
subgroups with greater mortality risk. These differential
outcomes underscore the need for dedicated trials in
these subpopulations.
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The presence of anemia is associated with worse outcomes
among many subgroups of patients including those with
chronic kidney disease (CKD), end stage renal disease, and
heart failure (HF).1–3 Paradoxically, however, trials compar-
ing the effects of the treatment of anemia to two different
hemoglobin goals in patients with CKD and end stage renal
disease demonstrated harm 4,5 in the subjects randomized to
the higher hemoglobin goals. This has led to hypotheses
regarding the potential for a direct relationship between the
erythrocyte-stimulating agent (ESA) dose and greater risk6 as
mechanisms for these worse outcomes.
Patients with HF who have either advanced disease or
recent hospitalization have a prevalence of anemia of 20% or
greater.7–11 As among patients with CKD, the presence of
anemia in those with HF is associated with an increased risk
of poorer outcomes.11 Because many patients with HF have
concurrent kidney disease related to the same underlying
comorbidities, some of the causes of anemia in these two
groups of patients (that is, CKD and HF) overlap. The term
‘cardiorenal syndrome’ has further been coined to identify
the overlap within patients for these two comorbidities as a
‘state in which therapy to relieve congestive heart failure
symptoms is limited by further worsening kidney function’.12
Although the large trials comparing outcomes between
treatment strategies for anemia in CKD and end stage renal
disease have been relatively consistent, trials comparing
outcomes among patients with HF and anemia have been
conflicting in terms of the effect of anemia management
using ESA on exercise tolerance and symptoms.13–15
To further refine knowledge on the impact of anemia
management among patients with comorbidities such as HF
and DM, two large trials (RED-HF and TREAT) are ongoing
to compare treatment with ESA to achieve hemoglobin goals
of greater than 13 g/dl to placebo. These trials will signi-
ficantly advance our understanding of how anemia treatment
with ESAs affects outcomes in these two populations.
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Given the use of the placebo arm, however, they will not be
able to shed light on the hemoglobin target that will best
maximize a benefit to therapy. CHOIR was a randomized
trial comparing the effect of treatment with epoetin-alfa to
one of two hemoglobin targets (11.3 vs 13.5 g/dl) on the
composite end point of death, hospitalization for congestive
heart failure, stroke, and myocardial infarction in CKD
patients with anemia. This secondary analysis of the CHOIR
trial was undertaken to compare outcomes among the
subgroups of patients with DM and HF to describe the com-
parative relationship with treatment to these two different
hemoglobin goals.
RESULTS
Description of subgroups based on HF and DM
As previously reported,5,6 1432 subjects were randomized in
CHOIR. Of these, 375 subjects had a previous history of HF,
whereas 967 had no previous history (Table 1) and 90
subjects had missing previous history. In general, subjects
with HF were older and were more likely to have concurrent
comorbidities such as DM, cerebrovascular disease, coronary
artery disease, peripheral vascular disease, and atrial dys-
rhythmias as compared with those without HF. Within sub-
groups based on the presence or absence of HF, there were
few differences between the two randomized treatment
groups. Of the entire cohort, 894 subjects had DM, 488 did
not, and 50 had missing information on the presence of DM.
Similar to the comparisons above, subjects with DM were
more likely to have concurrent comorbidities such as HF,
cerebrovascular disease, coronary artery disease, and periph-
eral vascular disease as compared with those without DM
(Table 2). And within subgroups based on the presence or
absence of DM, there were few differences between the two
randomized treatment groups.
Outcomes for subjects with and without HF
Subjects with HF had a greater hazard of experiencing a
primary end point than subjects without HF in a univariable
model (Po0.001) (Table 3a). Among subjects with HF,
Kaplan–Meier estimates of the 3-year failure rate for the
primary end point was 46.3% of those randomized to the
higher hemoglobin arm as compared with 50.8% of those
randomized to the lower hemoglobin arm (Figure 1a). These
differences were not significant (P¼ 0.643 based on Wald’s
w2-test from the unadjusted Cox model with interaction,
Table 3b). Of subjects without previous HF at baseline,
Kaplan–Meier estimates of the 3-year failure rate for the
primary end point was 22.7% of those randomized to the
higher hemoglobin arm as compared with only 14.2% of
those randomized to the lower hemoglobin arm (Figure 1b)
(P¼ 0.011 based on Wald’s w2 test from the unadjusted Cox
model with interaction, Table 3b).
The presence or absence of HF at baseline interac-
ted significantly with the hemoglobin target (P¼ 0.028)
(adjusted model, Table 3c). Other predictors for the occur-
rence of the primary end point included a previous history of
HF (Po0.001), lower serum albumin (Po0.001), increasing
age (Table 3c for spline P-values), previous cerebrovascular
disease (P¼ 0.042), previous deep venous thrombosis
(P¼ 0.009), previous atrial fibrillation or flutter (P¼ 0.002)
and previous malignancy (P¼ 0.046). The association
between cholesterol level and outcomes was not linear with
a decreasing risk as serum cholesterol rose to 240 mg/dl
(P¼ 0.015) followed by an increasing risk associated with
higher levels above that threshold (P¼ 0.003). The presence
of DM was not a significant predictor in this model.
In the adjusted model stratified on the presence or absence
of HF at baseline (Table 3c), there was no increased risk
associated with the higher target hemoglobin among subjects
with baseline HF (HR¼ 0.99; 95% CI 0.68, 1.43; PX0.99).
Among subjects without HF at baseline, the increased risk
associated with the higher target hemoglobin was highly
significant (HR¼ 1.86; 95% CI 1.21, 2.85; P¼ 0.004).
Outcomes for subjects with and without DM
Subjects with DM had a greater hazard of experiencing a
primary end point than subjects without DM (P¼ 0.067,
Table 4a). Among subjects with DM, Kaplan–Meier estimates
of the 3-year failure rate for the primary end point were
24.8% of those randomized to the higher hemoglobin arm as
compared with 24.7% of those randomized to the lower
hemoglobin arm (Figure 1c). These differences were not
significant (HR¼ 1.21, 95% CI 0.88, 1.67, P¼ 0.249 in the
unadjusted Cox model with interaction, Table 4a). Of
subjects without previous DM at baseline, Kaplan–Meier
estimates of the 3-year failure rate for the primary end point
were 36.4% of those randomized to the higher hemoglobin
arm as compared with only 24.0% of those randomized to
the lower hemoglobin arm (HR¼ 1.70, 95% CI 1.03, 2.81,
P¼ 0.040 in the unadjusted Cox model with interaction)
(Figure 1d, Table 4b). The presence or absence of DM at
baseline did not interact significantly with hemoglobin target
in either the unadjusted or adjusted models (Table 4b and c,
P¼ 0.265 and 0.559, respectively).
Because HF is more common in subjects with DM, the
potential for confounding of treatment effect within DM
subgroups by previous HF was investigated. The model with
all possible two-way and three-way interactions of treatment
failed to demonstrate a significant interaction among HF,
DM, and hemoglobin target (P¼ 0.674, model not shown).
Within four subgroups based on the presence or absence of
DM or HF the adjusted HR (95% CI; P-value) for hemo-
globin target were: (1) no previous CHF and no previous
DM: 1.96 (1.09, 3.52; P¼ 0.024), (2) no previous CHF and
previous DM: 1.75 (1.08,2.84; P¼ 0.023), (3) previous CHF
and no previous DM: 1.09 (0.61, 1.95; P¼ 0.999), and (4)
previous CHF and previous DM: 0.97 (0.65, 1.46; P¼ 0.895).
This indicates that for subjects without previous HF,
treatment effects (HR¼ 1.96 and 1.75) are similar and
significant for both patients without and with DM. For
subjects with HF, the treatment effects for patients without
and with DM again are similar, but not significant.
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DISCUSSION
CHOIR was a randomized trial that tested the effect of two
different hemoglobin targets among 1423 subjects with CKD
and anemia on cardiovascular outcomes. This secondary
analysis of the CHOIR trial examines this treatment effect
among subjects with and without diabetes mellitus and heart
failure. Although an increased risk of death, congestive heart
failure hospitalization, myocardial infarction and stroke was
shown in the group randomized to the higher arm in the
primary analysis, this secondary analysis suggests that the risk
was not homogeneous among these subgroups. In unadjusted
analyses, no differences in outcomes were seen between high
and low hemoglobin target groups for those subjects with
either of these two comorbidities. Conversely, the demon-
stration of increased risk in the higher hemoglobin target
group was entirely within those groups without diabetes or
Table 1 | Demographics and previous medical history for subjects grouped by presence or absence of HF at baseline
Subjects with HF at
baseline (N=375)
Subjects without HF at
baseline (N=967)
Hb 13.5
group
(N=192)
Hb 11.3
group
(N=183) P-value Total
Hb 13.5
group
(N=477)
Hb 11.3
group
(N=490) P-value Total
Age (years) 70.2 (11.71) 69.5 (11.26) 0.529 69.9 (11.49) 64.5 (14.98) 65.4 (13.98) 0.313 64.9 (14.48)
Male gender 89/192 (46.4%) 103/183 (56.3%) 0.054 192 (51.2%) 198/477 (41.5%) 212/490 (43.3%) 0.581 410 (42.4%)
Race: black (vs non-white/black) 56/191 (29.3%) 50/183 (27.3%) 0.668 106/374 (28.3%) 131/477 (27.5%) 146/490 (29.8%) 0.422 277/967 (28.6%)
Hispanic ethnicity 18/191 (9.4%) 22/183 (12.0%) 0.416 40/374 (10.7%) 66/476 (13.9%) 68/490 (13.9%) 0.996 134/966 (13.9%)
Diabetes mellitus 138/192 (71.9%) 143/183 (78.1%) 0.162 281/375 (74.9%) 281/476 (59.0%) 289/488 (59.2%) 0.953 570/964 (59.1%)
Previous CVA or TIA 31/192 (16.1%) 38/183 (20.8%) 0.249 69/375 (18.4%) 58/477 (12.2%) 60/488 (12.3%) 0.949 118/965 (12.2%)
Previous coronary artery disease 118/192 (61.5%) 116/183 (63.4%) 0.700 234/375 (62.4%) 115/477 (24.1%) 97/490 (19.8%) 0.105 212/967 (21.9%)
Previous peripheral vascular disease 51/192 (26.6%) 44/183 (24.0%) 0.575 95/375 (25.3%) 65/477 (13.6%) 70/488 (14.3%) 0.748 135/965 (14.0%)
Previous atrial fibrillation/flutter 43/192 (22.4%) 34/183 (18.6%) 0.360 77/375 (20.5%) 20/477 (4.2%) 24/490 (4.9%) 0.599 44/967 (4.6%)
History of solid organ malignancy 25/191 (13.1%) 24/183 (13.1%) 0.994 49/374 (13.1%) 65/472 (13.8%) 69/487 (14.2%) 0.859 134/959 (14.0%)
Inflammation/malnutrition (albuminp3.6 g/dl
or ferritin4600 ng/ml)
83/192 (43.2%) 68/179 (38.0%) 0.305 151/371 (40.7%) 180/475 (37.9%) 173/489 (35.4%) 0.417 353/964 (36.6%)
Baseline albumin (g/dl) 3.7 (0.55) 3.7 (0.48) 0.118 3.7 (0.52) 3.8 (0.50) 3.8 (0.46) 0.463 3.8 (0.48)
Baseline ferritin (ng/ml) 159.5 (142.08) 193.5 (186.05) 0.050 175.9 (165.41) 170.7 (163.08) 177.8 (169.36) 0.510 174.3 (166.25)
Baseline eGFR (ml/min) 26.9 (8.94) 26.0 (8.35) 0.291 26.5 (8.66) 27.0 (8.57) 28.0 (9.29) 0.103 27.5 (8.95)
Baseline cholesterol 172.5 (50.08) 178.5 (51.52) 0.254 175.4 (50.80) 189.8 (53.45) 186.5 (49.24) 0.318 188.1 (51.35)
Baseline TSAT (%) 22.1 (9.84) 24.1 (9.47) 0.043 23.1 (9.70) 26.4 (12.48) 25.1 (10.55) 0.069 25.7 (11.55)
Baseline hemoglobin 10.0 (0.96) 10.0 (0.96) 0.847 10.0 (0.96) 10.1 (0.83) 10.2 (0.85) 0.431 10.1 (0.84)
For age and baseline laboratory assessments, values presented are Mean (s.d.) and t-test P-values. Otherwise, n/N (%) and Pearson w2 P-values are provided.
CVA, cerebrovascular accident; eGFR, estimated glomerular filtration rate; HF, heart failure; TIA, transient ischemic attack; TSAT, transferrin saturation.
Table 2 | Summary of baseline characteristics among groups based on the presence or absence of DM at baseline
Subjects with DM at
baseline (N=894)
Subjects without DM at
baseline (N=488)
Hb 13.5
group (N=436)
Hb 11.3
group (N=458) P-value Total
Hb 13.5
group (N=249)
Hb 11.3
group (N=239) P-value Total
Age (years) 65.6 (12.37) 65.9 (11.42) 0.624 65.8 (11.89) 66.9 (17.10) 67.5 (16.32) 0.698 67.2 (16.70)
Male gender 193/436 (44.3%) 224/458 (48.9%) 0.164 417 (46.6%) 107/249 (43.0%) 97/239 (40.6%) 0.593 204 (41.8%)
Race: black (vs non-white/black) 136/435 (31.3%) 141/458 (30.8%) 0.877 277/893 (31.0%) 58/249 (23.3%) 64/239 (26.8%) 0.374 122/488 (25.0%)
Hispanic ethnicity 64/434 (14.7%) 75/457 (16.4%) 0.494 139/891 (15.6%) 24/249 (9.6%) 19/239 (7.9%) 0.511 43/488 (8.8%)
Previous HF composite 138/419 (32.9%) 143/432 (33.1%) 0.959 281/851 (33.0%) 54/249 (21.7%) 40/239 (16.7%) 0.166 94/488 (19.3%)
Previous CVA or TIA 60/420 (14.3%) 67/430 (15.6%) 0.596 127/850 (14.9%) 29/249 (11.6%) 31/239 (13.0%) 0.656 60/488 (12.3%)
Previous coronary artery disease 163/420 (38.8%) 153/432 (35.4%) 0.305 316/852 (37.1%) 70/249 (28.1%) 60/239 (25.1%) 0.452 130/488 (26.6%)
Previous peripheral vascular disease 88/419 (21.0%) 88/431 (20.4%) 0.833 176/850 (20.7%) 28/249 (11.2%) 26/238 (10.9%) 0.910 54/487 (11.1%)
Previous atrial fibrillation/flutter 32/419 (7.6%) 34/432 (7.9%) 0.899 66/851 (7.8%) 31/249 (12.4%) 24/239 (10.0%) 0.400 55/488 (11.3%)
History of solid organ malignancy 45/414 (10.9%) 52/431 (12.1%) 0.586 97/845 (11.5%) 45/249 (18.1%) 42/238 (17.6%) 0.903 87/487 (17.9%)
Inflammation/malnutrition
(albuminp3.6 g/dl or ferritin4600 ng/ml)
190/436 (43.6%) 190/453 (41.9%) 0.622 380/889 (42.7%) 85/247 (34.4%) 66/239 (27.6%) 0.105 151/486 (31.1%)
Baseline albumin (g/dl) 3.7 (0.53) 3.7 (0.46) 0.270 3.7 (0.49) 3.8 (0.50) 3.8 (0.47) 0.154 3.8 (0.48)
Baseline ferritin (ng/ml) 169.9 (154.62) 178.0 (167.38) 0.453 174.0 (161.21) 162.4 (164.58) 185.1 (182.28) 0.151 173.6 (173.70)
Baseline eGFR (ml/min) 27.0 (8.81) 27.5 (8.84) 0.434 27.2 (8.82) 27.0 (8.48) 26.9 (9.53) 0.953 26.9 (9.00)
Baseline cholesterol (mg/dl) 183.9 (54.57) 183.3 (49.95) 0.860 183.6 (52.23) 187.0 (49.07) 186.4 (48.88) 0.899 186.7 (48.93)
Baseline TSAT (%) 23.9 (10.17) 24.3 (9.61) 0.524 24.1 (9.88) 27.2 (14.13) 25.6 (11.14) 0.142 26.4 (12.76)
Baseline hemoglobin (g/dl) 10.0 (0.87) 10.1 (0.88) 0.018 10.0 (0.88) 10.3 (0.88) 10.2 (0.86) 0.177 10.2 (0.87)
For age and baseline laboratory assessments, values presented are Mean (s.d.) and t-test P-values. Otherwise, n/N (%) and Pearson w2 P-values are provided.
CVA, cerebrovascular accident; eGFR, estimated glomerular filtration rate; HF, heart failure; TIA, transient ischemic attack; TSAT, transferrin saturation.
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HF. In adjusted multivariable analyses, these relationships
were maintained among subjects based on the presence or
absence of HF. Among those subjects with HF, hemoglobin
goal did not appear to affect outcomes.
Although CHOIR and the Normalization of Hematocrit
Trial showed either harm or a strong trend toward harm,4,5
the mechanism by which targeting a higher hemoglobin
confers this risk is still not clear. A secondary analysis of the
CHOIR trial previously published suggested that higher doses
of epoetin-alfa are associated with a direct risk supported by
the fact that subjects targeted to a higher hemoglobin
required more epoetin-alfa.6 This relationship could not be
assessed among subgroups defined by DM or HF because of
the limited power within each related to sample size. If the
relationship between dose and risk were to be consistent
among all subgroups, one could hypothesize that the failure
to show a risk based on targeting a higher hemoglobin may
be related to the balance between competing risks and how
that balance differs in the presence of a comorbidity. Clearly,
the overall rate of experiencing an end point was greater
among subjects with either DM or HF than without. The
possibility that the risk imposed by targeting a higher
hemoglobin or receiving high doses of epoetin-alfa is not
clinically apparent in the setting of that higher baseline risk
should be considered and could be the mechanism for the
differential associations presented here.
The comparison of study design between CHOIR and
these two important trials of anemia correction in patients
with either HF (RED-HF) or DM (TREAT) must be
considered carefully before generalizing these results. With
respect to enrollment criteria, many trials assessing anemia
correction in HF require symptomatic heart failure with an
ejection fraction below a threshold (for example, 40%) and
test either a fixed dose or weight-based dose of ESA to
placebo. Although most do not have a target hemoglobin and
are phase II trials looking at intermediate outcomes,13–15 the
largest of the trials which is ongoing (RED-HF) has a goal
hemoglobin of at least 13.0 g/dl in the arm-receiving active
therapy and will be assessing morbidity and mortality.16 In
this secondary analysis of the CHOIR trial, it should be
recognized that the subgroup of subjects with HF were
identified based on past medical history questions rather
than objective echocardiographic criteria. Furthermore, the
clinical question being tested is subtly different between
trials. RED-HF is designed to compare active therapy to
placebo. In CHOIR, there was no placebo arm with all
patients receiving active therapy having been randomized to
one of two hemoglobin goals (11.3 vs 13.5 g/dl), and the trials
Table 3 | Univariate and multivariable Cox proportional hazard models of the primary composite event among subjects with
and without HF
Hazard ratio (95% CI) P-value
(a) Univariable model (n=1342, 90 excluded for missing information on HF)
Previous HF composite (HF, Cardiomyopathy, LVD, or RVD) vs no previous HF 4.08 (3.09, 5.37) o0.001
(b) Unadjusted model with interaction (n=1342, 90 excluded for missing information on HF)
Hb 13.5 g/dl (vs 11.3 g/dl) 1.73 (1.13, 2.65) 0.011
Previous HF composite (HF, Cardiomyopathy, LVD, or RVD) 5.29 (3.45, 8.12) o0.001
Interaction of Hb 13.5 g/dl group and previous HF composite 0.63 (0.36, 1.10) 0.105
Contrasts
No previous HF Patients—Hb 13.5 g/dl (vs Hb 11.3 g/dl) 1.73 (1.13, 2.65) 0.011
Prior HF Patients—Hb 13.5 g/dl (vs Hb 11.3 g/dl) 1.09 (0.76, 1.57) 0.643
(c) Adjusted multivariable model (n=1342, without missing HF with imputations for missing data in other fields)
Hb 13.5 g/dl (vs 11.3 g/dl) 1.86 (1.21, 2.85) 0.004
Baseline albumin (g/dl) 0.53 (0.40, 0.71) o0.001
Baseline cholesterol linear splines (per 10mg/dl)
o 240mg/dl 0.95 (0.92, 0.99) 0.015
X240mg/dl 1.09 (1.03, 1.16) 0.003
Age linear splines (per 5 years)
o55 years 1.55 (1.12, 2.15) 0.008
X55 to o75 years 0.97 (0.85, 1.10) 0.591
X75 years 1.41 (1.17, 1.70) o0.001
Previous HF composite (HF, cardiomyopathy, LVD, or RVD) 4.47 (2.89, 6.92) o0.001
Previous CVA or TIA 1.42 (1.01, 2.00) 0.042
Previous DVT 2.07 (1.20, 3.56) 0.009
History of solid organ malignancy 0.64 (0.41, 0.99) 0.046
Previous atrial fibrillation/flutter 1.77 (1.23, 2.54) 0.002
Interaction of Hb 13.5 g/dl group and previous HF composite 0.53 (0.30, 0.94) 0.028
Contrasts
No previous HF patients—Hb 13.5 g/dl (vs Hb 11.3 g/dl) 1.86 (1.21, 2.85) 0.004
Previous HF patients—Hb 13.5 g/dl (vs Hb 11.3 g/dl) 0.99 (0.68, 1.43) 40.999
For adjusted multivariable model, t-test P-values based on multiple imputation are provided. Otherwise, Wald w2 P-values are reported.
DVT, deep vein thrombosis; LVD, left ventricular dysfunction; RVD, right ventricular dysfunction.
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ask and answer two subtly different questions. If RED-HF
shows a benefit to ESA treatment as compared with placebo,
the results of the analysis presented here would be relevant to
designing trials that might test hemoglobin targets.
With respect to DM trials, the comparison of study
designs is similarly relevant. TREAT-randomized subjects
who are similar in many ways to the subjects enrolled in
CHOIR.17 The key design difference is that TREAT enrolled
only patients with type II DM. The analysis presented here
has the ability to identify patients based on a history of
diabetes supporting the comparison. However, in terms of
treatment arms, TREAT-randomized patients to receive
darbepoetin alfa to achieve and maintain target hemoglobin
of 13 g/dl or to the control arm-receiving placebo for
hemoglobin levels X9 g/dl with rescue therapy with darbe-
poetin alfa for hemoglobin levels o9 g/dl. If TREAT shows a
benefit to the arm-receiving active therapy, combined with
the results presented here, this suggests the hypothesis
that a goal of 11.3 is either equivalent to or a potentially
lower risk than the higher goal tested. At the time of this
analysis, however, preliminary results of the ITT analysis
of TREAT showed no statistically significant effect of
treatment18 qualitatively similar to the univariate analysis
presented here.
The major limitations of this analysis include the
consideration of the validity of post hoc subgroup analyses
as well as the limited power that exists within subgroups in
the cohort. The limitations of subgroup analyses particularly
with respect to chance findings have been widely dis-
cussed.19–21 These limitations are relevant considerations in
the interpretation of the subgroup analyses presented here.
Although chance findings may result in a significant result
among subgroups where no treatment effect was seen in the
overall cohort, the subgroups without HF or DM had a
treatment effect similar in direction to the overall cohort. The
relevant consideration here should therefore be focused on
the lack of treatment effect among those patients with HF or
DM. The interpretation of these findings must be considered
in the context of the decreased power afforded within
each subgroup. The potential for a type II error because of
the decreased power within these subgroups particularly
among the analyses based on the presence or absence of DM
must be considered. In addition, given that subjects were
identified as having HF based on their self-reported history
or documentation in their medical record, the potential
for misclassification is present. Although misclassification
generally biases against finding a difference between groups,
this limitation should be considered.
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Figure 1 |Kaplan–Meier plot of the primary end point. (a) Subjects with a previous history of HF. (b) Subjects without a previous history
of HF. (c) Subjects with diabetes mellitus. (d) Subjects without diabetes mellitus.
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Table 4 | Univariate and multivariable Cox proportional hazard models of the primary composite event among subjects with
and without DM
Hazard ratio 95% CI P-value
(a) Univariate models (n=1382, 50 excluded for missing information on DM)
Previous DM (history or etiology) vs no DM 1.31 (0.98, 1.76) 0.067
(b) Unadjusted model with interaction (n=1382, 50 excluded for missing information on DM)
Hb 13.5 g/dl (vs 11.3 g/dl) 1.70 (1.03, 2.81) 0.040
Previous DM (history or etiology) 1.61 (1.01, 2.56) 0.044
Interaction of Hb 13.5 g/dl group*previous DM (history or etiology) 0.71 (0.39, 1.29) 0.265
Contrasts
No previous DM patients—Hb 13.5 g/dl (vs Hb 11.3 g/dl) 1.70 (1.03, 2.81) 0.040
Previous DM patients—Hb 13.5 g/dl (vs Hb 11.3 g/dl) 1.21 (0.88, 1.67) 0.249
(c) Adjusted multivariate model (n=1382, 50 excluded for missing information on DM)
Hb 13.5 g/dl (vs 11.3 g/dl) 1.47 (0.88, 2.45) 0.143
Baseline albumin (g/dl) 0.55 (0.41, 0.72) o0.001
Baseline cholesterol linear splines (per 10mg/dl)
o 240mg/dl 0.96 (0.93, 1.00) 0.053
X240mg/dl 1.09 (1.02, 1.15) 0.006
Age linear splines (per 5 years)
o55 years 1.50 (1.09, 2.05) 0.012
X55 to o75 years 0.96 (0.85, 1.09) 0.555
X75 years 1.44 (1.19, 1.74) o0.001
Previous CHF composite (CHF, cardiomyopathy, LVD, or RVD) 2.97 (2.22, 3.98) o0.001
Previous CVA or TIA 1.48 (1.05, 2.10) 0.028
Previous DVT 1.99 (1.15, 3.44) 0.014
History of solid organ malignancy 0.65 (0.42, 1.02) 0.059
Previous atrial fibrillation/flutter 1.77 (1.22, 2.58) 0.003
Previous DM (history or etiology) 1.37 (0.85, 2.21) 0.198
Interaction of Hb 13.5 g/dl group*previous DM (history or etiology) 0.83 (0.45, 1.53) 0.559
Contrasts
No previous DM patients—Hb 13.5 g/dl (vs Hb 11.3 g/dl) 1.47 (0.88, 2.45) 0.143
Previous DM patients—Hb 13.5 g/dl (vs Hb 11.3 g/dl) 1.22 (0.88, 1.69) 0.225
(d) Adjusted multivariate model (n=1339, 93 subjects excluded for missing information on HF or DM)
Hb 13.5 g/dl (vs 11.3 g/dl) 1.96 (1.09, 3.52) 0.024
Baseline albumin (g/dl) 0.53 (0.40, 0.71) o0.001
Baseline cholesterol linear splines (per 10mg/dl)
o240mg/dl 0.96 (0.92, 0.99) 0.017
X240mg/dl 1.10 (1.03, 1.16) 0.003
Age linear splines (per 5 years)
o55 years 1.53 (1.10, 2.12) 0.011
X55 to o75 years 0.97 (0.85, 1.11) 0.692
X75 years 1.42 (1.17, 1.72) o0.001
Previous CHF composite (CHF, cardiomyopathy, LVD, or RVD) 4.30 (2.76, 6.69) o0.001
Previous CVA or TIA 1.42 (1.01, 2.00) 0.042
Previous DVT 2.10 (1.22, 3.61) 0.005
History of solid organ malignancy 0.65 (0.42, 1.02) 0.060
Previous atrial fibrillation/flutter 1.79 (1.24, 2.60) 0.002
Previous DM (history or etiology) 1.25 (0.77, 2.03) 0.367
Interaction of Hb 13.5 g/dl group*previous CHF composite 0.56 (0.31, 0.98) 0.043
Interaction of Hb 13.5 g/dl group*previous DM (history or etiology) 0.90 (0.48, 1.66) 0.724
Contrasts
Hb 13.5 g/dl (vs Hb 11.3 g/dl) within the following patient subgroups:
No previous CHF and no previous DM patients 1.96 (1.09, 3.52) 0.024
No previous CHF and previous DM patients 1.75 (1.08, 2.84) 0.023
Previous CHF and no previous DM patients 1.09 (0.61, 1.95) 40.999
Previous CHF and previous DM patients 0.97 (0.65, 1.46) 0.895
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This secondary analysis of the CHOIR trial looks at the
effect of treating anemia in CKD to two different treatment
goals based on clinical subgroups defined by HF and DM.
These results suggest that the presence of these comorbidi-
ties attenuates the risk seen in the group randomized to the
higher hemoglobin goal. These results will either serve
to validate the important findings of RED-HF and TREAT
or will serve as an example of the need for careful
interpretation of subgroup analyses of completed trials.
Although the mechanism for this differential treatment effect
might be due to the stronger effect of the comorbidity on
outcome (that is, competing risk), this is not clear. However,
it does allow a continued focus as to the subgroups of
patients in whom the risk associated with higher treat-
ment goal and potentially higher ESA dose is potentially
concentrated or conversely not statistically or clinically
apparent. Although these results do not support the
correction of hemoglobin to 13 gm/dl in these subgroups,
they allow us to clinically hone in on strategies to safely
maximize the exercise tolerance of those with comorbidities
and minimize the potential detrimental effects on those
without comorbidities.
MATERIALS AND METHODS
Description of data set
CHOIR was a randomized trial comparing the effect of treat-
ment with epoetin-alfa to one of two hemoglobin targets on the
composite end point of death, hospitalization for congestive heart
failure, stroke, and myocardial infarction in CKD patients with
anemia. Methods, baseline characteristics, and results of CHOIR
have been reported.5 Inclusion criteria were hemoglobino11.0 g/dl
and MDRD glomerular filtration rate (GFR) of 15–50 ml/
min per 1.73 m2.
Definition of variables
A past medical history of the following diseases or conditions was
defined as the presence of one or more of the variables in the case
report form. Coronary artery disease was defined as the presence of
past myocardial infarction, angina at baseline, or previous coronary
artery bypass grafting or percutaneous coronary intervention. Heart
failure (HF) was defined as a history of congestive heart failure,
cardiomyopathy, left ventricular dysfunction, or right ventricular
dysfunction reported by the subject or in the medical record.
Diabetes mellitus (DM) was defined as either the presence of a
history of or etiology of renal failure by type 1 or 2 DM.
Cerebrovascular disease was defined as a previous history of either
a stroke or transient ischemic attack. Thromboembolic disease was
defined as a previous history of pulmonary embolism, arterial or
deep venous thrombosis, or a hypercoaguable state. Peripheral
vascular disease was defined as the presence of either peripheral
vascular disease or lower extremity amputation. A single composite
variable reflecting the presence of either malnutrition or inflamma-
tion was defined as a baseline serum albuminp3.6 g/dl or
ferritin4600 ng/ml.
Analyses
The primary goal of this analysis was to identify differences in the
primary composite outcome between randomization arms within
clinically relevant subgroups defined by the presence or absence of
heart failure (HF) and diabetes mellitus (DM). Descriptive statistics
were examined based on Kaplan–Meier survival curves for subjects
randomized to each treatment arm within the subgroups of interest
and the unadjusted treatment effect was obtained based on the
Wald test from Cox proportional hazard models containing the
main effects of treatment and HF (or DM) and the interaction of HF
(or DM) with treatment.
To estimate the adjusted treatment effects within the subgroups,
Cox proportional hazards regressions with the backward selection
process at a stay level of 0.05 was used to select baseline variables for
adjustment. The bootstrap method was used in combination with
the backwards Cox proportional hazard regression analysis to select
the final set of baseline variables included in the adjusted model.
In the bootstrap procedure, 200 samples of 80% of the 1432
patients were sampled at random with replacement. A Cox
proportional hazards regression with the stepwise selection process
at an entry level of 0.10 and a stay level of 0.05 was applied to every
bootstrap sample. If the variable occurred in at least 50% of the
bootstrap models, the variable was judged to be reliable and was
included in the adjusted model.22 Candidate variables for the model
included baseline laboratory measurements (eGFR, albumin, total
cholesterol, ferritin, transferrin saturation (TSAT), hemoglobin,
protein/creatinine ratio, and the composite indicating the presence
of inflammation or malnutrition defined as albumin p3.6 or
ferritin4600) and demographic and clinical measurements (age,
gender, race, ethnicity, coronary artery disease, HF, DM, cerebro-
vascular disease, thromboembolic disease, hypertension, peripheral
vascular disease, any malignancy, cigarette smoking and previous
atrial fibrillation). The treatment variable was always included in
the model selection process. For continuous variables whose effect
is not linear, piecewise linear splines with cut points based on
minimizing the –2 log likelihood were used. Multiple imputation
method was used to impute all missing data so that the model
development was based on all original 1432 patients. Specifically,
missing data were imputed via Markov Chain Monte Carlo method
that draws simulation from a Bayesian predictive distribution based
on the demographic, medical history, previous medication and
baseline lab data. For binary variables where the randomly drawn
values are X0.5, the imputed values were set to 1 and 0 otherwise.
For continuous variables, in which the randomly drawn values are
less than (or greater than) the minimum (or maximum) of the
observed values for the variables, the imputed values were set to the
minimum (or maximum) of the observed values. Five imputed data
sets were generated using SAS procedure MI. The s.e. for the
parameter estimates were obtained by using the SAS procedure
MIANALYZE to account for uncertainty because of imputation.
The variables selected in this process are used for the adjustment
described below.
The selected variables in the final model were used to obtain
the adjusted treatment effect within subgroups defined by the
absence or presence of HF or DM based on models including the
interaction of HF with treatment or the interaction of DM with
treatment. Specifically, to evaluate the treatment effect within
subgroups defined by HF, subjects without missing baseline HF
were used for the models. The unadjusted model includes the
main effects of HF and treatment and the interaction of HF and
treatment. The adjusted model contains these factors as well as the
main effects of all selected variables for adjustment. The subgroup
comparisons were carried out by forming contrasts in the models
to estimate the treatment effect within the subgroups of presence
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or absence of HF. Similarly, the treatment effect within subgroups
defined by the absence or presence of DM was investigated based
on subjects without missing baseline DM in an unadjusted model
with the main effects of DM and treatment and the interaction of
DM and treatment as well as an adjusted model containing these
factors plus the selected variables. Because HF is more common in
subjects with DM, the potential for confounding of treatment
effects by HF within DM subgroups was investigated. The
treatment effects within four subgroups: no prior HF and no
prior DM, no prior HF and prior DM, prior HF and no prior DM,
prior HF and prior DM were examined through all possible two-
way and three-way interactions of treatment, HF and DM in the
fully adjusted model. Multiple imputation method described
above was used to deal with missing data in the selected variables
for adjustment. Analyses were also performed on data sets without
imputation providing similar results (data not shown). All
statistical analyses were performed using SAS (version 9.2, SAS
Institute, Cary, NC, USA). A P-value p0.05 was considered as
statistically significant.
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